AU2002365260A1 - Replication competent dual-ad vectors for vaccine and immunotherapy applications - Google Patents

Replication competent dual-ad vectors for vaccine and immunotherapy applications

Info

Publication number: AU2002365260A1
Authority: AU; Australia
Prior art keywords: vaccine; vectors; dual; replication competent; immunotherapy applications
Prior art date: 2001-10-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002365260A

Other versions

AU2002365260A8 (en

Inventor

Nathan P. Englund

Xiangming Fang

Mark I. Fitchmun

Scott Gallichan

Amena Rahman

Sybille Sauter

Robert E. Sobol

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genstar Therapeutics Corp

Original Assignee

Genstar Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-16

Filing date

2002-10-16

Publication date

2003-09-02

2002-10-16 Application filed by Genstar Therapeutics Corp filed Critical Genstar Therapeutics Corp

2003-09-02 Publication of AU2002365260A1 publication Critical patent/AU2002365260A1/en

2007-12-20 Publication of AU2002365260A8 publication Critical patent/AU2002365260A8/en

Status Abandoned legal-status Critical Current

Links

238000009169 immunotherapy Methods 0.000 title 1
230000010076 replication Effects 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1
239000013598 vector Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Cardiology (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2002365260A 2001-10-16 2002-10-16 Replication competent dual-ad vectors for vaccine and immunotherapy applications Abandoned AU2002365260A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32979801P	2001-10-16	2001-10-16
US60/329,798		2001-10-16
PCT/US2002/033079 WO2003061560A2 (en)	2001-10-16	2002-10-16	Replication competent dual-ad vectors for vaccine and immunotherapy applications

Publications (2)

Publication Number	Publication Date
AU2002365260A1 true AU2002365260A1 (en)	2003-09-02
AU2002365260A8 AU2002365260A8 (en)	2007-12-20

Family

ID=23287062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002365260A Abandoned AU2002365260A1 (en)	2001-10-16	2002-10-16	Replication competent dual-ad vectors for vaccine and immunotherapy applications

Country Status (5)

Country	Link
EP (1)	EP1450862A4 (en)
JP (1)	JP2005511534A (en)
AU (1)	AU2002365260A1 (en)
CA (1)	CA2463996A1 (en)
WO (2)	WO2003061560A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR8302354U (en)	2003-09-17	2004-05-18	Orlando Rossi Jr	Improvement introduced in phototherapeutic light source for treatment of hyperbilirubinemia
US9746471B2 (en)	2008-01-25	2017-08-29	Multivir Inc.	P53 biomarkers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403370B1 (en) *	1997-02-10	2002-06-11	Genstar Therapeutics Corporation	Oncolytic/immunogenic complementary-adenoviral vector system
EP1287153B1 (en) *	2000-05-31	2009-09-30	Human Gene Therapy Research Institute	Methods and compositions for efficient gene transfer using transcomplementary vectors

2002
- 2002-10-16 EP EP02770603A patent/EP1450862A4/en not_active Withdrawn
- 2002-10-16 AU AU2002365260A patent/AU2002365260A1/en not_active Abandoned
- 2002-10-16 JP JP2003535831A patent/JP2005511534A/en active Pending
- 2002-10-16 WO PCT/US2002/033079 patent/WO2003061560A2/en not_active Application Discontinuation
- 2002-10-16 WO PCT/US2002/033162 patent/WO2003033029A1/en not_active Application Discontinuation
- 2002-10-16 CA CA 2463996 patent/CA2463996A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2003061560A3 (en)	2007-10-18
WO2003061560A2 (en)	2003-07-31
WO2003033029A1 (en)	2003-04-24
AU2002365260A8 (en)	2007-12-20
EP1450862A4 (en)	2005-03-02
EP1450862A1 (en)	2004-09-01
JP2005511534A (en)	2005-04-28
CA2463996A1 (en)	2003-04-24

Legal Events

Date	Code	Title	Description
2004-07-01	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase

Publication	Publication Date	Title
AU2002336760A1 (en)	2003-06-10	Mutable vaccines
AU2002234643A1 (en)	2003-02-27	Amphoteric liposomes and the use thereof
AU2003235707A1 (en)	2003-07-30	Immunogenic preparations and vaccines on the basis of mrna
AU2002351623A1 (en)	2003-07-09	Streptococcus antigens
AU2002315389A1 (en)	2003-01-08	Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002315388A1 (en)	2003-01-08	Novel phenylamino-pyrimidines and uses thereof
AU2003224313A1 (en)	2003-11-17	Mycobacterial antigens and uses thereof
AU2002255649A1 (en)	2002-09-19	Band 3 antigenic peptides, malaria polypeptides and uses thereof
WO2005065382A8 (en)	2008-10-23	Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
AU2002243314A1 (en)	2002-06-24	Immunogenic cancer peptides and uses thereof
AU2002212049A1 (en)	2003-05-15	Novel silicone material, its preparation method and the use thereof
AU2003267361A1 (en)	2004-04-30	Orthopoxvirus antigens and use thereof
AU2002312373A1 (en)	2002-12-23	Structural and cytoskeleton-associated proteins
AU2002347464A1 (en)	2003-01-02	Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2002365260A1 (en)	2003-09-02	Replication competent dual-ad vectors for vaccine and immunotherapy applications
AU2002320079A1 (en)	2002-12-23	Vaccines, immunotherapeutics and methods of using the same
AU2002335838A1 (en)	2003-04-28	Replication competent dual-ad vectors for vaccine and immunotherapy applications
AUPR548601A0 (en)	2001-06-28	Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2002303093A1 (en)	2002-09-12	Mycobacterial vaccines
AU2002320621A1 (en)	2003-03-03	Structural and cytoskeleton-associated proteins
AU2002343516A1 (en)	2003-04-22	Structural and cytoskeleton-associated proteins
AU2002306879A1 (en)	2002-10-15	Cytoskeleton-associated proteins
AU2002354188B2 (en)	2008-11-27	Novel peptides and medicinal uses thereof
AU2002302831A1 (en)	2003-01-02	Inactivated mycobacterial ompatb and uses thereof
AUPR589701A0 (en)	2001-07-19	Novel peptide and use thereof